Association of early tumor shrinkage with survival in patients with HER2-positive advanced gastric cancer treated with trastuzumab deruxtecan.

被引：0
|
作者：
Fukuda, Koshiro
Ooki, Akira
Osumi, Hiroki
Fukuoka, Shota
Yoshino, Koichiro
Tamba, Mikako
Udagawa, Shohei
Shimozaki, Keitaro
Ogura, Mariko
Wakatsuki, Takeru
Chin, Keisho
Fujishiro, Mitsuhiro
Shinozaki, Eiji
Yamaguchi, Kensei
机构：
[1] Canc Inst Hosp Japanese Fdn Canc Res, Dept Gastroenterol Chemotherapy, Tokyo, Japan
[2] Canc Inst Hosp Japanese Fdn Canc Res, Dept Gastroenterol Chemotherapy, Koto, Japan
[3] Univ Tokyo, Dept Gastroenterol, Tokyo, Japan
[4] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.360
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：360 / 360
页数：1
相关论文
共 50 条
  • [11] A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy
    Dongwoo Chae
    Chung Mo Nam
    Joo Hoon Kim
    Choong-Kun Lee
    Seung-Seob Kim
    Hyo Song Kim
    Minkyu Jung
    Jae Ho Cheong
    Hyun Cheol Chung
    Sun Young Rha
    Kyungsoo Park
    The AAPS Journal, 20
  • [12] A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy
    Chae, Dongwoo
    Nam, Chung Mo
    Kim, Joo Hoon
    Lee, Choong-Kun
    Kim, Seung-Seob
    Kim, Hyo Song
    Jung, Minkyu
    Cheong, Jae Ho
    Chung, Hyun Cheol
    Rha, Sun Young
    Park, Kyungsoo
    AAPS JOURNAL, 2018, 20 (04):
  • [13] Survival of patients with HER2-positive gastric cancer with introduction of trastuzumab.
    Shitara, Kohei
    Yatabe, Yasushi
    Sugano, Masato
    Matsuo, Keitaro
    Kondo, Chihiro
    Takahari, Daisuke
    Ura, Takashi
    Tajika, Masahiro
    Muro, Kei
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [14] Trastuzumab Deruxtecan in HER2-positive metastatic Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2024, 84 (08) : 670 - 670
  • [15] Trastuzumab deruxtecan in the treatment of adult patients with HER2-positive breast cancer
    Kufel-Grabowska, Joanna
    ONCOLOGY IN CLINICAL PRACTICE, 2023, 19 (05): : 377 - 381
  • [16] Trastuzumab deruxtecan and other HER2-targeting agents for the treatment of HER2-positive gastric cancer
    Ishii, Takahiro
    Shitara, Kohei
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (11) : 1193 - 1201
  • [17] Association between HER2 heterogeneity and clinical outcomes of HER2-positive gastric cancer patients treated with trastuzumab
    Kyunghye Bang
    Jaekyung Cheon
    Young Soo Park
    Hyung-Don Kim
    Min-Hee Ryu
    Yangsoon Park
    Meesun Moon
    Hyungeun Lee
    Yoon-Koo Kang
    Gastric Cancer, 2022, 25 : 794 - 803
  • [18] Association between HER2 heterogeneity and clinical outcomes of HER2-positive gastric cancer patients treated with trastuzumab
    Bang, Kyunghye
    Cheon, Jaekyung
    Park, Young Soo
    Kim, Hyung-Don
    Ryu, Min-Hee
    Park, Yangsoon
    Moon, Meesun
    Lee, Hyungeun
    Kang, Yoon-Koo
    GASTRIC CANCER, 2022, 25 (04) : 794 - 803
  • [19] Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
    Park, Ji Soo
    Youn, Jong-Chan
    Shim, Chi Young
    Hong, Geu-Ru
    Lee, Choong-Kun
    Kim, Jee Hyung
    Park, Hyung Soon
    Heo, Su Jin
    Beom, Seung Hoon
    Kim, Hyo Song
    Rha, Sun Young
    Chung, Hyun Cheol
    Kang, Seok-Min
    Jung, Minkyu
    ONCOTARGET, 2017, 8 (37) : 61837 - 61845
  • [20] Metabolic heterogeneity affects trastuzumab response and survival in HER2-positive advanced gastric cancer
    Wang, Jun
    Sun, Na
    Kunzke, Thomas
    Shen, Jian
    Feuchtinger, Annette
    Wang, Qian
    Meixner, Raphael
    LeGleut, Ronan
    Haffner, Ivonne
    Luber, Birgit
    Lordick, Florian
    Walch, Axel
    BRITISH JOURNAL OF CANCER, 2024, 130 (06) : 1036 - 1045
12345